China drug stock surges after doctor endorses its treatment for Covid
Guangzhou
A MAKER of traditional Chinese medicine products saw its stock surge the most in two years on Friday after one of the nation's top medical advisers reportedly said one of its treatments could potentially inhibit Covid-19.
Speculative traders pushed Guangzhou Baiyunshan Pharmaceutical Holdings up 13 per cent in Hong Kong and by its 10 per cent limit in Shanghai. Guangzhou-based Nanfang Daily cited Zhong Nanshan as saying Baiyunshan's "banlangen" product was effective in a series of in-vitro studies. Mr Zhong is a senior medical adviser to Beijing who confirmed the risk of human-to-human Covid-19 infection on Jan 20.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
UK's FTSE 100 hits record highs on Anglo-American boost
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
SocGen Q1 profit slumps less than expected as investment bank surprises
Wall Street Journal moves Asia headquarters from Hong Kong to Singapore
Macquarie sees biggest profit dip in 15 years on commodities downturn
HSBC appoints ex-Citi banker as new Singapore head of global banking